Cargando…

Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients

PURPOSE: This prospective clinical trial investigated sodium ((23)Na) MRI at 7 Tesla (T) field strength as biomarker for tumor extent, isocitrate dehydrogenase (IDH) mutation and O6-methylguanine DNA methyltransferase (MGMT) promotor methylation in glioma patients. METHODS: 28 glioma patients underw...

Descripción completa

Detalles Bibliográficos
Autores principales: Regnery, Sebastian, Behl, Nicolas G.R., Platt, Tanja, Weinfurtner, Nina, Windisch, Paul, Deike-Hofmann, Katerina, Sahm, Felix, Bendszus, Martin, Debus, Jürgen, Ladd, Mark E., Schlemmer, Heinz-Peter, Rieken, Stefan, Adeberg, Sebastian, Paech, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527584/
https://www.ncbi.nlm.nih.gov/pubmed/33002860
http://dx.doi.org/10.1016/j.nicl.2020.102427
_version_ 1783589089097809920
author Regnery, Sebastian
Behl, Nicolas G.R.
Platt, Tanja
Weinfurtner, Nina
Windisch, Paul
Deike-Hofmann, Katerina
Sahm, Felix
Bendszus, Martin
Debus, Jürgen
Ladd, Mark E.
Schlemmer, Heinz-Peter
Rieken, Stefan
Adeberg, Sebastian
Paech, Daniel
author_facet Regnery, Sebastian
Behl, Nicolas G.R.
Platt, Tanja
Weinfurtner, Nina
Windisch, Paul
Deike-Hofmann, Katerina
Sahm, Felix
Bendszus, Martin
Debus, Jürgen
Ladd, Mark E.
Schlemmer, Heinz-Peter
Rieken, Stefan
Adeberg, Sebastian
Paech, Daniel
author_sort Regnery, Sebastian
collection PubMed
description PURPOSE: This prospective clinical trial investigated sodium ((23)Na) MRI at 7 Tesla (T) field strength as biomarker for tumor extent, isocitrate dehydrogenase (IDH) mutation and O6-methylguanine DNA methyltransferase (MGMT) promotor methylation in glioma patients. METHODS: 28 glioma patients underwent (23)Na MRI on a 7T scanner (Siemens Healthcare, Erlangen, Germany) parallel to standard 3T MRI before chemoradiation. Areas of Gadolinium-contrast enhancement (gdce), non-enhancing T2-hyperintensity (regarded as edema), necrosis, and normal-appearing white matter (nawm) were segmented on 3T MRI imaging and were co-registered with the (23)Na images. The median total (23)Na concentrations of all areas were compared by pairwise t-tests. Furthermore, areas of gdce and edema were merged to yield the whole tumor area without necrosis. Subsequently, the difference in median of the (23)Na concentration of this whole tumor area was compared between IDH-mutated and IDH wild-type gliomas as well as MGMT methylated and MGMT not-methylated glioblastomas using Whitney-Mann U-tests. All p-values were corrected after the Bonferroni-Holm procedure. RESULTS: The (23)Na concentration increased successively from nawm to necrotic areas (mean ± sd: nawm = 37.84 ± 5.87 mM, edema = 54.69 ± 10.64 mM, gdce = 61.72 ± 12.95 mM, necrosis = 81.88 ± 17.53 mM) and the concentrations differed statistically significantly between all regarded areas (adjusted p-values for all pairwise comparisons < 0.05). Furthermore, IDH-mutated gliomas showed significantly higher (23)Na concentrations than IDH wild-type gliomas (median [interquartile range]: IDH wild-type = 52.37 mM [45.98 – 58.56 mM], IDH mutated = 65.02 mM [58.87–67.05 mM], p = 0.039). Among the glioblastomas, there was a trend towards increased (23)Na concentration in MGMT methylated tumors that did not reach statistical significance (median [interquartile range]: MGMT methylated = 57.59 mM [50.70 – 59.17 mM], MGMT not methylated = 48.78 mM [45.88 – 53.91 mM], p = 1.0). CONCLUSIONS: (23)Na MRI correlates with the IDH mutation status and could therefore enhance image guidance towards biopsy sites as wells as image-guided surgery and radiotherapy. Furthermore, the successive decrease of (23)Na concentration from central necrosis to normal-appearing white matter suggests a correlation with tumor infiltration.
format Online
Article
Text
id pubmed-7527584
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75275842020-10-05 Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients Regnery, Sebastian Behl, Nicolas G.R. Platt, Tanja Weinfurtner, Nina Windisch, Paul Deike-Hofmann, Katerina Sahm, Felix Bendszus, Martin Debus, Jürgen Ladd, Mark E. Schlemmer, Heinz-Peter Rieken, Stefan Adeberg, Sebastian Paech, Daniel Neuroimage Clin Regular Article PURPOSE: This prospective clinical trial investigated sodium ((23)Na) MRI at 7 Tesla (T) field strength as biomarker for tumor extent, isocitrate dehydrogenase (IDH) mutation and O6-methylguanine DNA methyltransferase (MGMT) promotor methylation in glioma patients. METHODS: 28 glioma patients underwent (23)Na MRI on a 7T scanner (Siemens Healthcare, Erlangen, Germany) parallel to standard 3T MRI before chemoradiation. Areas of Gadolinium-contrast enhancement (gdce), non-enhancing T2-hyperintensity (regarded as edema), necrosis, and normal-appearing white matter (nawm) were segmented on 3T MRI imaging and were co-registered with the (23)Na images. The median total (23)Na concentrations of all areas were compared by pairwise t-tests. Furthermore, areas of gdce and edema were merged to yield the whole tumor area without necrosis. Subsequently, the difference in median of the (23)Na concentration of this whole tumor area was compared between IDH-mutated and IDH wild-type gliomas as well as MGMT methylated and MGMT not-methylated glioblastomas using Whitney-Mann U-tests. All p-values were corrected after the Bonferroni-Holm procedure. RESULTS: The (23)Na concentration increased successively from nawm to necrotic areas (mean ± sd: nawm = 37.84 ± 5.87 mM, edema = 54.69 ± 10.64 mM, gdce = 61.72 ± 12.95 mM, necrosis = 81.88 ± 17.53 mM) and the concentrations differed statistically significantly between all regarded areas (adjusted p-values for all pairwise comparisons < 0.05). Furthermore, IDH-mutated gliomas showed significantly higher (23)Na concentrations than IDH wild-type gliomas (median [interquartile range]: IDH wild-type = 52.37 mM [45.98 – 58.56 mM], IDH mutated = 65.02 mM [58.87–67.05 mM], p = 0.039). Among the glioblastomas, there was a trend towards increased (23)Na concentration in MGMT methylated tumors that did not reach statistical significance (median [interquartile range]: MGMT methylated = 57.59 mM [50.70 – 59.17 mM], MGMT not methylated = 48.78 mM [45.88 – 53.91 mM], p = 1.0). CONCLUSIONS: (23)Na MRI correlates with the IDH mutation status and could therefore enhance image guidance towards biopsy sites as wells as image-guided surgery and radiotherapy. Furthermore, the successive decrease of (23)Na concentration from central necrosis to normal-appearing white matter suggests a correlation with tumor infiltration. Elsevier 2020-09-12 /pmc/articles/PMC7527584/ /pubmed/33002860 http://dx.doi.org/10.1016/j.nicl.2020.102427 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Regular Article
Regnery, Sebastian
Behl, Nicolas G.R.
Platt, Tanja
Weinfurtner, Nina
Windisch, Paul
Deike-Hofmann, Katerina
Sahm, Felix
Bendszus, Martin
Debus, Jürgen
Ladd, Mark E.
Schlemmer, Heinz-Peter
Rieken, Stefan
Adeberg, Sebastian
Paech, Daniel
Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients
title Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients
title_full Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients
title_fullStr Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients
title_full_unstemmed Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients
title_short Ultra-high-field sodium MRI as biomarker for tumor extent, grade and IDH mutation status in glioma patients
title_sort ultra-high-field sodium mri as biomarker for tumor extent, grade and idh mutation status in glioma patients
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527584/
https://www.ncbi.nlm.nih.gov/pubmed/33002860
http://dx.doi.org/10.1016/j.nicl.2020.102427
work_keys_str_mv AT regnerysebastian ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT behlnicolasgr ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT platttanja ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT weinfurtnernina ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT windischpaul ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT deikehofmannkaterina ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT sahmfelix ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT bendszusmartin ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT debusjurgen ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT laddmarke ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT schlemmerheinzpeter ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT riekenstefan ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT adebergsebastian ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients
AT paechdaniel ultrahighfieldsodiummriasbiomarkerfortumorextentgradeandidhmutationstatusingliomapatients